Actually, ANRIL has been previously proved to specifically inhibit the expression of let-7a in tumors, including prostate cancer [30] and nasopharyngeal carcinoma [14], showing that let-7a reduced expression in ovarian cancer may be affected by the regulation of ANRIL. Here, CDKN2B-AS1 is linked to nasopharyngeal carcinoma.